The United States Food and Drug Administration (FDA) and the Australian Therapeutic Goods Administration (TGA) recently approved one such agent, vorasidenib, for adult and pediatric patients 12 years and older with grade 2 astrocytoma or oligodendroglioma with a susceptible IDH1 or IDH2 mutation (103). Here, IDH1 is linked to astrocytoma (excluding glioblastoma).